Sign In
Buy CRMD
$8.32
-0.0800 (-0.95%)
At Close: Jul 13, 2026
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
12:10pm, Tuesday, 30'th Jun 2026
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
12:10pm, Tuesday, 30'th Jun 2026
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
12:06pm, Tuesday, 30'th Jun 2026
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
08:30am, Monday, 08'th Jun 2026
PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of th
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run
01:36pm, Wednesday, 27'th May 2026
CorMedix is rated a 'Strong Buy' below ~$8.35, with ~114% upside to a $17.5 fair value based on DCF modeling. CRMD faces a 2027 revenue trough post-TDAPA, but I expect growth to reignite from 2027 to
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
06:05am, Friday, 22'nd May 2026
CorMedix NASDAQ: CRMD CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
11:16am, Friday, 15'th May 2026
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
08:30am, Friday, 15'th May 2026
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Ca
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
01:54pm, Thursday, 14'th May 2026
CorMedix Therapeutics Inc. (NASDAQ:CRMD) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting strong first-quarter results driven by higher utilization of DefenCath and contr
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
12:40pm, Thursday, 14'th May 2026
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
CorMedix Q1 Earnings Call Highlights
10:09am, Thursday, 14'th May 2026
CorMedix NASDAQ: CRMD reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while manageme
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
09:46am, Thursday, 14'th May 2026
CorMedix (CRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.3 per share a year ago.
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
07:30am, Thursday, 14'th May 2026
‒ Q1 2026 Net Revenue of $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA Guidance ‒ ‒ C
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:00am, Thursday, 07'th May 2026
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
08:30am, Tuesday, 05'th May 2026
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the
